Ligand Pharmaceuticals (NASDAQ:LGND) Cut to Hold at StockNews.com

StockNews.com lowered shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) from a buy rating to a hold rating in a research note released on Wednesday morning. Several other brokerages also recently weighed in on LGND. HC Wainwright reaffirmed a buy rating and set a $144.00 target price on shares of Ligand Pharmaceuticals in a research […]

Related Keywords

Chicago ,Illinois ,United States , ,Ziegler Capital Management ,Ligand Pharmaceuticals Incorporated ,Ligand Pharmaceuticals ,Chicago Capital ,Barclays ,News Ratings For Ligand Pharmaceuticals Daily ,Norges Bank ,Ligand Pharmaceuticals Company Profile ,Pacer Advisors Inc ,Ligand Pharmaceuticals Stock Performance ,Free Report ,Moderate Buy ,Get Free Report ,Capital Management ,Pharmaceuticals Incorporated ,Ligand Pharmaceuticals Daily ,Nasdaq Lgnd ,Lgnd ,Medical ,53220k50 ,Downgrade ,Stocknews Com ,